The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Will The Market Size Of The Anemia And Other Blood Disorder Drugs Market Progress Through 2030?
The anemia and other blood disorder drugs market size has observed strong growth recently. It is projected to increase from $12.46 billion in 2025 to $13.14 billion in 2026, displaying a compound annual growth rate (CAGR) of 5.5%. The expansion witnessed in the past can be linked to factors such as a high incidence of iron deficiency anemia, the prevalence of chronic kidney disease, the dependence on blood transfusions, the prolonged application of esAs, and established hematology treatment protocols.
The anemia and other blood disorder drugs market size is anticipated to experience significant expansion over the coming years. It is projected to grow to $16.88 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. This growth within the forecast period is attributed to factors such as the increasing adoption of gene therapy, a rising aging population, greater awareness of blood disorders, the expansion of specialty hematology clinics, and improved diagnostic rates. Prominent trends for the forecast period include the increasing prevalence of chronic blood disorders, a growing use of injectable therapies, the expansion of gene therapy for rare anemias, an increasing focus on personalized hematology treatments, and enhanced access to essential blood disorder drugs.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2465&type=smp
Which Growth Drivers Are Expected To Support The Anemia And Other Blood Disorder Drugs Market Forward?
The increasing demand for personalized medicine is anticipated to drive the future growth of the anemia and other blood disorder drugs market. Personalized medicine is a medical methodology that leverages an individual’s genetic profile to inform prevention, diagnosis, and treatment strategies. The rise in demand for personalized medicine stems from its capability to deliver more effective, targeted therapies that enhance patient outcomes and long-term health. The anemia and other blood disorder drugs market supports personalized care by enabling individualized treatment plans designed to address the specific genetic or molecular characteristics of blood disorders. For instance, in May 2024, according to the American Psychiatric Association, a US-based non-profit organization, 43% of adults report feeling more anxious than they did the year before, an increase from 37% in 2023 and 32% in 2022. Consequently, the escalating demand for personalized medicine is propelling the expansion of the anemia and other blood disorder drugs market.
What Are The Core Segment Classifications In The Anemia And Other Blood Disorder Drugs Market?
The anemia and other blood disorder drugs market covered in this report is segmented –
1) By Type: Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia
2) By Route of Administration: Oral, Injectable
3) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy
Subsegments:
1) By Iron Deficiency Anemia: Oral Iron Supplements, Injectable Iron Supplements, Iron Fortified Foods
2) By Chronic Kidney Disease Anemia: Erythropoiesis-Stimulating Agents (ESAs), Iron Supplements, Blood Transfusion
3) By Sickle Cell Anemia: Hydroxyurea, Blood Transfusions, Gene Therapy, Pain Management Drugs
4) By Aplastic Anemia: Immunosuppressive Therapy, Stem Cell Transplantation, Erythropoiesis-Stimulating Agents (ESAs)
Which Trends Are Guiding The Development Of The Anemia And Other Blood Disorder Drugs Market?
Major companies in the anemia and other blood disorder drugs market are concentrating on introducing innovative medications to elevate therapeutic outcomes, expand treatment options, and strengthen their competitive standing. Novel medications are defined as advanced pharmaceutical therapies that offer new mechanisms of action, superior effectiveness, or enhanced safety profiles compared to existing treatments, thereby addressing unmet medical needs in conditions such as anemia and myelodysplastic syndromes. For example, in August 2023, Bristol-Myers Squibb Company, a US-based pharmaceutical company, received FDA approval for Reblozyl for use as the first-line treatment of anemia in adults with lower-risk myelodysplastic syndromes. This marked the first therapy to demonstrate superiority over an erythropoiesis-stimulating agent in this setting, supported by Phase 3 COMMANDS trial data revealing that nearly twice as many Reblozyl-treated patients achieved at least 12 weeks of transfusion independence with concurrent hemoglobin improvement compared to those receiving Epoetin alfa.
Which Organizations Are Involved In The Anemia And Other Blood Disorder Drugs Market?
Major companies operating in the anemia and other blood disorder drugs market are Amgen Inc, GlaxoSmithKline plc, Akebia Therapeutics Inc., Bayer AG, Pfizer Inc, F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Global Blood Therapeutics Inc., Eli Lilly and Company, FibroGen Inc., bluebird bio Inc., Acceleron Pharma Inc., AMAG Pharmaceuticals Inc., Vifor Pharma Management Ltd., Sanofi S.A., AbbVie Inc., Johnson & Johnson, Daiichi Sankyo Company Limited, Pharmacosmos A/S, Emmaus Medical Inc., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck & Co. Inc., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc., Grifols S.A.
Access The Complete Anemia And Other Blood Disorder Drugs Market Report:
Which Region Contributes The Most To The Anemia And Other Blood Disorder Drugs Market?
North America was the largest region in the anemia and other blood disorder drugs market in 2025. Middle East is expected to be the fastest-growing region in the anemia and other blood disorder drugs market during the forecast period. The regions covered in the anemia and other blood disorder drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Anemia And Other Blood Disorder Drugs Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=2465&type=smp
Browse Through More Reports Similar to the Global Anemia And Other Blood Disorder Drugs Market 2026, By The Business Research Company
Anemia And Other Blood Disorder Drugs Market Report 2026
Chemotherapy Induced Anemia Market Report 2026
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report
Hematology Drug Market Report 2026
https://www.thebusinessresearchcompany.com/report/hematology-drug-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model